Patents by Inventor Naoki Toyooka
Naoki Toyooka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11479537Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.Type: GrantFiled: September 21, 2018Date of Patent: October 25, 2022Assignees: KINKI UNIVERSITY, NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Atsufumi Kawabata, Fumiko Sekiguchi, Maho Tsubota, Naoki Toyooka, Hiroyuki Nishikawa
-
Patent number: 11365194Abstract: This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: GrantFiled: September 27, 2018Date of Patent: June 21, 2022Assignees: KAGOSHIMA UNIVERSITY, SHOWA UNIVERSITYInventors: Takashi Kurihara, Ichiro Takasaki, Naoki Toyooka, Hiroaki Gouda
-
Publication number: 20220184081Abstract: This invention relates to an antipruritic agent of formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: ApplicationFiled: February 12, 2020Publication date: June 16, 2022Applicant: KAGOSHIMA UNIVERSITYInventors: Takashi KURIHARA, lchiro TAKASAKl, Naoki TOYOOKA, Hiroaki GOUDA
-
Publication number: 20210188841Abstract: This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.Type: ApplicationFiled: September 27, 2018Publication date: June 24, 2021Applicants: KAGOSHIMA UNIVERSITY, SHOWA UNIVERSITYInventors: Takashi KURIHARA, Ichiro TAKASAKI, Naoki TOYOOKA, Hiroaki GOUDA
-
Publication number: 20200308132Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.Type: ApplicationFiled: September 21, 2018Publication date: October 1, 2020Inventors: Atsufumi KAWABATA, Fumiko SEKIGUCHI, Maho TSUBOTA, Naoki TOYOOKA, Hiroyuki NISHIKAWA
-
Patent number: 9216954Abstract: A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR?_1], [LW_1], and [ED_1] as an active ingredient.Type: GrantFiled: January 24, 2013Date of Patent: December 22, 2015Assignee: NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMAInventors: Hisashi Mori, Naoki Toyooka, Mineyuki Mizuguchi, Takayuki Obita, Syuichi Hirono, Hiroaki Goda
-
Publication number: 20140371291Abstract: A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR?_1], [LW_1], and [ED_1] as an active ingredient.Type: ApplicationFiled: January 24, 2013Publication date: December 18, 2014Inventors: Hisashi Mori, Naoki Toyooka, Mineyuki Mizuguchi, Takayuki Obita, Syuichi Hirono, Hiroaki Goda
-
Patent number: 8198447Abstract: A fused tricyclic compound having aldose reductase inhibitory activity and shown by the following formula, wherein R1 represents 1 to 3 atoms or substituents selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl, cycloalkyl, alkylene, or alkoxy group, and a protected or unprotected hydroxyl or carboxyl group, R2 represents a protected or unprotected carboxyl group, R3 represents 1 or 2 atoms or substituents selected from a hydrogen atom, a halogen atom, an oxo group, a substituted or unsubstituted alkyl or alkoxy group, and a protected or unprotected carboxyl group, A represents an alkylene group, and B represents an oxygen atom, a sulfur atom, or a group shown by the following formula, wherein R4 represents an alkyl or aryl group substituted by an aryl, cycloalkyl, or heterocyclic group, and X represents an oxygen atom or a sulfur atom, provided that, when B represents a group shown by the following formula: wherein R4 represents an alkyl or aryl group substitutedType: GrantFiled: February 11, 2010Date of Patent: June 12, 2012Assignee: National University Corporation University of ToyamaInventors: Naoki Toyooka, Atsushi Kato, Isao Adachi
-
Publication number: 20100145052Abstract: A fused tricyclic compound having aldose reductase inhibitory activity and shown by the following formula, wherein R1 represents 1 to 3 atoms or substituents selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl, cycloalkyl, alkylene, or alkoxy group, and a protected or unprotected hydroxyl or carboxyl group, R2 represents a protected or unprotected carboxyl group, R3 represents 1 or 2 atoms or substituents selected from a hydrogen atom, a halogen atom, an oxo group, a substituted or unsubstituted alkyl or alkoxy group, and a protected or unprotected carboxyl group, A represents an alkylene group, and B represents an oxygen atom, a sulfur atom, or a group shown by the following formula, wherein R4 represents an alkyl or aryl group substituted by an aryl, cycloalkyl, or heterocyclic group, and X represents an oxygen atom or a sulfur atom, provided that, when B represents a group shown by the following formula: wherein R4 represents an alkyl or aryl group substituted wiType: ApplicationFiled: February 11, 2010Publication date: June 10, 2010Applicant: National University Corporation University of ToyamaInventors: Naoki TOYOOKA, Atsushi KATO, Isao ADACHI